用于糖尿病视网膜病变筛查的人工智能系统:对美国FDA批准的第三种算法- AEYE-DS的评估

Sunny Chi Lik Au
{"title":"用于糖尿病视网膜病变筛查的人工智能系统:对美国FDA批准的第三种算法- AEYE-DS的评估","authors":"Sunny Chi Lik Au","doi":"10.46889/joar.2023.4202","DOIUrl":null,"url":null,"abstract":"Artificial Intelligence (AI) has revolutionized the field of healthcare in recent years, and one of its most promising applications is on the interpretation of medical images [1]. In ophthalmology, the first success comes to the screening and diagnosis of Diabetic Retinopathy (DR) [2]. DR is a common complication of Diabetes Mellitus (DM) that affects the eyes, and early detection and treatment is crucial in preventing vision loss, especially over the working populations [3]. The use of AI in DR screening involves analyzing digital fundus images to detect any signs of DR, including microaneurysms, dot and blot haemorrhages, cotton-wool spots, venous beading, intraretinal microvascular anomalies [4]. Currently, there are 3 US FDA approved systems on DR screening, IDx-DR (Digital Diagnostics), EyeArt (Eyenuk, Inc) and AEYE-DS (AEYE Health, Inc) [5-7]. AI has several advantages over traditional screening methods, including usage by non-ophthalmologically trained medical personnel, accessible and stable performance over whatever time and place, increased speed of clinical workflow, these might potentially help to improve outcomes for patients with DM. In the era of rapidly advancing technology, the use of AI in ophthalmology is an exciting development that might transform our future practice [8]. In this appraisal, we focus on the 3rd US FDA approved AI algorithms for DR.","PeriodicalId":348405,"journal":{"name":"Journal of Ophthalmology and Advance Research","volume":"32 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Artificial Intelligence Systems for Diabetic Retinopathy Screening: Appraisal on the 3rd US FDA Approved Algorithms- AEYE-DS\",\"authors\":\"Sunny Chi Lik Au\",\"doi\":\"10.46889/joar.2023.4202\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Artificial Intelligence (AI) has revolutionized the field of healthcare in recent years, and one of its most promising applications is on the interpretation of medical images [1]. In ophthalmology, the first success comes to the screening and diagnosis of Diabetic Retinopathy (DR) [2]. DR is a common complication of Diabetes Mellitus (DM) that affects the eyes, and early detection and treatment is crucial in preventing vision loss, especially over the working populations [3]. The use of AI in DR screening involves analyzing digital fundus images to detect any signs of DR, including microaneurysms, dot and blot haemorrhages, cotton-wool spots, venous beading, intraretinal microvascular anomalies [4]. Currently, there are 3 US FDA approved systems on DR screening, IDx-DR (Digital Diagnostics), EyeArt (Eyenuk, Inc) and AEYE-DS (AEYE Health, Inc) [5-7]. AI has several advantages over traditional screening methods, including usage by non-ophthalmologically trained medical personnel, accessible and stable performance over whatever time and place, increased speed of clinical workflow, these might potentially help to improve outcomes for patients with DM. In the era of rapidly advancing technology, the use of AI in ophthalmology is an exciting development that might transform our future practice [8]. In this appraisal, we focus on the 3rd US FDA approved AI algorithms for DR.\",\"PeriodicalId\":348405,\"journal\":{\"name\":\"Journal of Ophthalmology and Advance Research\",\"volume\":\"32 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Ophthalmology and Advance Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.46889/joar.2023.4202\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmology and Advance Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46889/joar.2023.4202","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

近年来,人工智能(AI)彻底改变了医疗保健领域,其最有前途的应用之一是医学图像的解释[1]。在眼科,首先成功的是糖尿病视网膜病变(Diabetic Retinopathy, DR)的筛查和诊断[2]。DR是糖尿病(DM)常见的影响眼睛的并发症,早期发现和治疗对于预防视力丧失至关重要,尤其是在工作人群中[3]。人工智能在DR筛查中的应用包括分析数字眼底图像,以发现DR的任何迹象,包括微动脉瘤、点状出血、棉絮斑、静脉珠状、视网膜微血管异常[4]。目前,美国FDA批准了3种DR筛查系统,分别是IDx-DR (Digital Diagnostics)、EyeArt (Eyenuk, Inc)和AEYE- ds (AEYE Health, Inc)[5-7]。人工智能与传统筛查方法相比有几个优势,包括非眼科培训的医务人员可以使用,在任何时间和地点都可以获得稳定的性能,提高了临床工作流程的速度,这些可能有助于改善糖尿病患者的预后。在技术快速发展的时代,人工智能在眼科中的应用是一项令人兴奋的发展,可能会改变我们未来的实践[8]。在本次评估中,我们重点关注美国FDA批准的第三种DR人工智能算法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Artificial Intelligence Systems for Diabetic Retinopathy Screening: Appraisal on the 3rd US FDA Approved Algorithms- AEYE-DS
Artificial Intelligence (AI) has revolutionized the field of healthcare in recent years, and one of its most promising applications is on the interpretation of medical images [1]. In ophthalmology, the first success comes to the screening and diagnosis of Diabetic Retinopathy (DR) [2]. DR is a common complication of Diabetes Mellitus (DM) that affects the eyes, and early detection and treatment is crucial in preventing vision loss, especially over the working populations [3]. The use of AI in DR screening involves analyzing digital fundus images to detect any signs of DR, including microaneurysms, dot and blot haemorrhages, cotton-wool spots, venous beading, intraretinal microvascular anomalies [4]. Currently, there are 3 US FDA approved systems on DR screening, IDx-DR (Digital Diagnostics), EyeArt (Eyenuk, Inc) and AEYE-DS (AEYE Health, Inc) [5-7]. AI has several advantages over traditional screening methods, including usage by non-ophthalmologically trained medical personnel, accessible and stable performance over whatever time and place, increased speed of clinical workflow, these might potentially help to improve outcomes for patients with DM. In the era of rapidly advancing technology, the use of AI in ophthalmology is an exciting development that might transform our future practice [8]. In this appraisal, we focus on the 3rd US FDA approved AI algorithms for DR.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信